	US 11,701,349 B2
	Pharmaceutical composition containing quinoline derivative
Xinhua Zhang, Lianyungang (CN); Chenyang Wang, Lianyungang (CN); Daimei Zhang, Lianyungang (CN); and Jianfeng Bai, Lianyungang (CN)
Assigned to JIANGSU HENGRUI MEDICINE CO., LTD., Jiangsu (CN)
Appl. No. 16/757,363
Filed by JIANGSU HENGRUI MEDICINE CO., LTD., Jiangsu (CN)
PCT Filed Oct. 23, 2018, PCT No. PCT/CN2018/111388 § 371(c)(1), (2) Date Apr. 17, 2020, PCT Pub. No. WO2019/080830, PCT Pub. Date May 2, 2019.
Claims priority of application No. 201711002771.4 (CN), filed on Oct. 24, 2017.
Prior Publication US 2021/0186952 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4709 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)

CPC A61K 31/4709 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2095 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01)]

17 Claims

1. A pharmaceutical composition comprising an active ingredient (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy) phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidinyl-2-yl)-acrylamide or a pharmacologically acceptable salt thereof, a disintegrant, a filler, an adhesive and a lubricant;

the pharmaceutical composition is obtained by a) mixing the active ingredient (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy) phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidinyl-2-yl)-acrylamide or the pharmacologically acceptable salt thereof with the disintegrant, the filler, and the adhesive;

b) wet granulating by adding a wetting agent;

c) fluidized drying;

d) adding the lubricant and mixing; and

e) compressing into tablets or filling into capsules;

wherein the wetting agent is ethanol or ethanol and water, wherein the disintegrant is cross-linked polyvinyl pyrrolidone, and wherein the wet granulating is fluidized bed spray granulating.